Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer
Crossref DOI link: https://doi.org/10.1007/s00345-015-1621-5
Published Online: 2015-06-19
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kitagawa, Yasuhide
Ueno, Satoru
Izumi, Kouji
Kadono, Yoshifumi
Mizokami, Atsushi
Hinotsu, Shiro
Akaza, Hideyuki
Namiki, Mikio
Text and Data Mining valid from 2015-06-19